Bayer shares slump after court tells firm to pay $2.25 billion over Monsanto weedkiller lawsuit
By Louis Goss
Shares in Bayer fell 5% on Monday after a Philadelphia jury told the German pharmaceutical company to pay $2.25 billion to a man who says he developed cancer due to using its Roundup branded weedkiller.
A jury at Philadelphia Court of Common Pleas awarded John McKivision $2 billion in punitive damages and an additional $250 million in compensatory damages in ruling the claimant developed non-Hodgkin's lymphoma as a result of exposure to Bayer's glyphosate-based weedkiller.
Shares in Bayer (DE:BAYA) fell 5% on Monday having lost 46% of their value over the past 12 months.
Bayer has faced around 165,000 lawsuits from Roundup customers who claim they developed cancer due to using the glyphosate-based weedkiller, which was first developed by Monsanto in the 1970s, prior to the U.S. company's acquisition by Bayer for $66 billion in 2018.
"The jury's punitive damages award sends a clear message that this multi-national corporation needs top to bottom change," McKivision's attorneys Tom Kline and Jason Itkin told Reuters. Lawyers acting for McKivision were contacted by MarketWatch for comment.
In a statement, Bayer vowed to appeal the Philadelphia court's decision. The German company has repeatedly denied that exposure to its glyphosate-based weedkiller is responsible for its customers developing illnesses.
"We cannot understand the jury's verdict, which contradicts the scientific evidence and the assessments of regulators around the world," Bayer said in a statement.
"We are confident that we have strong arguments on appeal to overturn this verdict or at least reduce the unconstitutionally excessive damages."
Bayer said even in cases it's lost, damages have been reduced by 90%, and that it's won 10 of the 16 Roundup lawsuits.
"We will continue to litigate cases because it has been proven that we win cases when plaintiffs' attorneys cannot misrepresent the scientific and regulatory assessments," the company added.
-Louis Goss
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
01-29-24 0814ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now